Completed PHASE4 INTERVENTIONAL 2-arm NCT03540823

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

Sponsor: University of Sao Paulo General Hospital

Conditions Sjogren's Syndrome Systemic Lupus

Interventions Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)

Updated 5 times since 2018 Last updated: Apr 25, 2019 Started: Apr 23, 2018 Primary completion: Jun 23, 2018 Completion: Aug 23, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Sjogren's Syndrome and Systemic Lupus, this trial is completed. The trial is conducted by University of Sao Paulo General Hospital and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — May 2019 [monthly]

Recruiting PHASE4

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sao Paulo General Hospital

Data source: University of Sao Paulo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil